Lilly’s eczema drug shows durable long-term response in late-stage study

March 27 (Reuters) – Eli Lilly said on Friday that its eczema drug showed durable results in a late-stage post-marketing study, such as  relief from persistent  itch for up to four years in patients with the skin condition.

Here are more details:

* A once-monthly injection of the drug, Ebglyss – approvedin the United States in 2024 – showed durable response inpatients with moderate-to-severe atopic dermatitis, which causesintense itching. * The injectable treatment is approved for adults andchildren 12 years and older with moderate-to-severe eczema whocannot use topical therapies. * In the study, majority of patients achieved near-completeskin clearance and itch relief with up to four years ofcontinuous treatment, Lilly said. * Ebglyss’ safety in the first year of the study wasconsistent with its known profile, regardless of dosingfrequency, and no new safety issues were observed, the companysaid. * The study will continue for an additional year oftreatment. * Lilly last year reported results from another trialshowing Ebglyss provided a durable response when dosed everyfour or eight weeks. The drugmaker said it has submitted thedata to the U.S. Food and Drug Administration for a potentiallabel update.

(Reporting by Sneha S K in Bengaluru; Editing by Diti Pujara)